The study evaluated the addition of oral Xeloda to Herceptin and Taxotere in patients with HER2-positive breast cancer who were previously untreated for their locally advanced, or metastatic, disease.

• 此项调查对HER2阳性乳腺癌在使用赫赛汀和泰素帝的基础上在口服希罗达进行了评估，这些患者以前并没有对局部晚期或转移性乳腺癌进行治疗。